Heather Blair has received a 2026 Global Recognition Award across three categories for her patient advocacy work in raising public awareness of ...

South Coast doctors perform first nose-based brain tumour surgery, marking a major KZN breakthrough and improving access to ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

Tenosynovial giant cell tumor is a locally aggressive tumor of the joint synovium, bursae or tendon sheaths. Although rare and not life-threatening, it can cause significant pain, stiffness and joint ...

Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; refractory or vision-threatening disease may need ONSF or CSF shunting.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Neurosurgeons at the BC Children’s Hospital are giving Tumber Ridge shooting victim Maya Gebala a “brain holiday,” according ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

A small reset in fair value to €143.20, together with individual analyst targets moving to €135 from €150 and to €130 from €125, has put fresh focus on how Merck KGaA is being framed right now. These ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...